CN102665711A - 青蒿素基药物与其他化学治疗剂的抗癌组合物 - Google Patents

青蒿素基药物与其他化学治疗剂的抗癌组合物 Download PDF

Info

Publication number
CN102665711A
CN102665711A CN2010800580524A CN201080058052A CN102665711A CN 102665711 A CN102665711 A CN 102665711A CN 2010800580524 A CN2010800580524 A CN 2010800580524A CN 201080058052 A CN201080058052 A CN 201080058052A CN 102665711 A CN102665711 A CN 102665711A
Authority
CN
China
Prior art keywords
cancer
iminomethylcamptothecin
chemotherapeutic
agent
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800580524A
Other languages
English (en)
Chinese (zh)
Inventor
C·皮萨诺
L·维西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN102665711A publication Critical patent/CN102665711A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800580524A 2009-12-23 2010-12-06 青蒿素基药物与其他化学治疗剂的抗癌组合物 Pending CN102665711A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09180666 2009-12-23
EP09180666.1 2009-12-23
PCT/EP2010/068924 WO2011076547A1 (en) 2009-12-23 2010-12-06 Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents

Publications (1)

Publication Number Publication Date
CN102665711A true CN102665711A (zh) 2012-09-12

Family

ID=41647059

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800580524A Pending CN102665711A (zh) 2009-12-23 2010-12-06 青蒿素基药物与其他化学治疗剂的抗癌组合物

Country Status (21)

Country Link
US (1) US9023861B2 (https=)
EP (1) EP2515898A1 (https=)
JP (1) JP2013515690A (https=)
KR (1) KR20120096053A (https=)
CN (1) CN102665711A (https=)
AR (1) AR079654A1 (https=)
AU (1) AU2010335422A1 (https=)
BR (1) BR112012015606A2 (https=)
CA (1) CA2780591A1 (https=)
EA (1) EA201200934A1 (https=)
IL (1) IL220561A0 (https=)
IN (1) IN2012DN03914A (https=)
MX (1) MX2012006738A (https=)
MY (1) MY157475A (https=)
NZ (1) NZ599878A (https=)
PH (1) PH12012500893A1 (https=)
SG (1) SG10201408485SA (https=)
TW (1) TWI482621B (https=)
UA (1) UA107691C2 (https=)
WO (1) WO2011076547A1 (https=)
ZA (1) ZA201205360B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105963262A (zh) * 2016-06-06 2016-09-28 北京林业大学 一种新型两亲性果胶-双氢青蒿素纳米粒子的制备
CN109453156A (zh) * 2018-11-22 2019-03-12 中国中医科学院中药研究所 一种抗肿瘤组合物及其应用、抗肿瘤药物
CN110051850A (zh) * 2016-08-26 2019-07-26 宁国市厚普生物科技有限公司 一种复合物在制备用于治疗黑色素瘤的药物中的应用
CN114010643A (zh) * 2021-11-23 2022-02-08 温州医科大学 双氢青蒿素在抗肿瘤药物的制备中的应用
CN114053271A (zh) * 2020-07-30 2022-02-18 江苏天士力帝益药业有限公司 一种含有tsl-1502m的药物组合物及其应用
CN114053276A (zh) * 2020-07-30 2022-02-18 江苏天士力帝益药业有限公司 一种parp抑制剂tsl-1502中间体tsl-1502m的用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2013177420A2 (en) * 2012-05-23 2013-11-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of bcr-abl positive lymphoblastic leukemias
US20170049815A1 (en) * 2014-05-02 2017-02-23 Emory University Selective Chemotherapy Treatments and Diagnostic Methods Related Thereto
US9918972B2 (en) * 2014-12-23 2018-03-20 The University Of Maryland, Baltimore Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents
EP3868372A1 (en) * 2020-02-19 2021-08-25 JLP Health GmbH A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
CN1758905A (zh) * 2003-02-12 2006-04-12 乔治敦大学 青蒿素在治疗致癌病毒诱导的肿瘤和治疗病毒感染中的应用
CN101125140A (zh) * 2007-09-18 2008-02-20 浙江大学 二氢青蒿素在增强化疗药物抗肿瘤疗效中的应用
CN101380325A (zh) * 2008-10-23 2009-03-11 上海交通大学 青蒿素衍生物与长春瑞滨的组合物及其应用
CN101428034A (zh) * 2008-12-12 2009-05-13 广州市允中投资发展有限公司 具有增效减毒特点的抗肿瘤组合药物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216998T1 (de) 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
KR100390332B1 (ko) 2000-08-02 2003-07-07 유원민 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물
EP1658844A1 (en) 2004-10-19 2006-05-24 Gerold Schuler Use of artemisinin derivatives in the manufacture of a medicament for the treatment of melanoma
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US8143284B2 (en) * 2006-10-05 2012-03-27 Abbott Laboratories Poly(ADP-ribose)polymerase inhibitors
CN101784268B (zh) 2006-11-20 2013-06-19 赛福伦公司 使用辐射敏化剂使肿瘤对辐射敏化的方法
WO2009114459A2 (en) * 2008-03-10 2009-09-17 The Trustees Of The University Of Pennsylvania Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein
CN101856352A (zh) * 2009-04-10 2010-10-13 中国科学院上海生命科学研究院 青蒿素及其衍生物对化疗剂的协同作用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
CN1758905A (zh) * 2003-02-12 2006-04-12 乔治敦大学 青蒿素在治疗致癌病毒诱导的肿瘤和治疗病毒感染中的应用
CN101125140A (zh) * 2007-09-18 2008-02-20 浙江大学 二氢青蒿素在增强化疗药物抗肿瘤疗效中的应用
CN101380325A (zh) * 2008-10-23 2009-03-11 上海交通大学 青蒿素衍生物与长春瑞滨的组合物及其应用
CN101428034A (zh) * 2008-12-12 2009-05-13 广州市允中投资发展有限公司 具有增效减毒特点的抗肿瘤组合药物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
张祖贻，等: "青蒿琥酯联合NP 方案治疗中晚期非小细胞肺癌的随机对照研究", 《中西医结合学报》, vol. 6, no. 2, 28 February 2008 (2008-02-28), pages 134 - 138 *
李燕飞，等: "青蒿素抗肿瘤作用的研究进展", 《热带医学杂志》, vol. 9, no. 3, 31 March 2009 (2009-03-31), pages 341 - 342 *
阮栋梁等: "青蒿素的制备、用途和展望", 《渤海大学学报(自然科学版)》, vol. 28, no. 2, 30 June 2007 (2007-06-30), pages 108 - 112 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105963262A (zh) * 2016-06-06 2016-09-28 北京林业大学 一种新型两亲性果胶-双氢青蒿素纳米粒子的制备
CN105963262B (zh) * 2016-06-06 2018-11-30 北京林业大学 一种两亲性果胶-双氢青蒿素纳米粒子的制备方法
CN110051850A (zh) * 2016-08-26 2019-07-26 宁国市厚普生物科技有限公司 一种复合物在制备用于治疗黑色素瘤的药物中的应用
CN109453156A (zh) * 2018-11-22 2019-03-12 中国中医科学院中药研究所 一种抗肿瘤组合物及其应用、抗肿瘤药物
CN114053271A (zh) * 2020-07-30 2022-02-18 江苏天士力帝益药业有限公司 一种含有tsl-1502m的药物组合物及其应用
CN114053276A (zh) * 2020-07-30 2022-02-18 江苏天士力帝益药业有限公司 一种parp抑制剂tsl-1502中间体tsl-1502m的用途
CN114053271B (zh) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 一种含有tsl-1502m的药物组合物及其应用
CN114053276B (zh) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 一种parp抑制剂tsl-1502中间体tsl-1502m的用途
CN114010643A (zh) * 2021-11-23 2022-02-08 温州医科大学 双氢青蒿素在抗肿瘤药物的制备中的应用

Also Published As

Publication number Publication date
SG10201408485SA (en) 2015-01-29
AU2010335422A1 (en) 2012-06-07
UA107691C2 (ru) 2015-02-10
IL220561A0 (en) 2012-08-30
TW201138764A (en) 2011-11-16
BR112012015606A2 (pt) 2018-05-29
MY157475A (en) 2016-06-15
CA2780591A1 (en) 2011-06-30
WO2011076547A1 (en) 2011-06-30
JP2013515690A (ja) 2013-05-09
PH12012500893A1 (en) 2012-11-12
EA201200934A1 (ru) 2012-12-28
EP2515898A1 (en) 2012-10-31
US20120258181A1 (en) 2012-10-11
IN2012DN03914A (https=) 2015-09-04
ZA201205360B (en) 2013-05-29
MX2012006738A (es) 2012-07-03
NZ599878A (en) 2014-06-27
AR079654A1 (es) 2012-02-08
KR20120096053A (ko) 2012-08-29
US9023861B2 (en) 2015-05-05
TWI482621B (zh) 2015-05-01

Similar Documents

Publication Publication Date Title
TWI482621B (zh) 青蒿素基藥物與其他化學治療劑的抗癌組合物
CN111886006B (zh) 治疗肥大细胞增多症的组合疗法
JP6637884B2 (ja) ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
CN102215838B (zh) 烷酰基l-肉毒碱联合化学治疗药在治疗赘生物中的应用
CN112294965B (zh) Mdm2抑制剂的药物组合物及其在预防和/或治疗疾病中的用途
KR20220003560A (ko) 유잉 육종의 치료를 위한 퀴놀린 화합물 또는 그의 약제학적으로 허용 가능한 염
TW201127384A (en) Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
KR20220113411A (ko) KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
WO2014180304A1 (zh) J1-001化合物作为抗癌药物的用途
WO2014002922A1 (ja) 抗癌剤の併用による癌治療方法
WO2023011488A1 (zh) 一种药物组合及其用途
HK1173090A (en) Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents
CN109789136B (zh) 用于预防或治疗结肠直肠癌的药物联合组合物
WO2023078408A1 (zh) 含met受体酪氨酸激酶抑制剂的药物组合及应用
CN121335700A (zh) 三并环类抑制剂与抗癌剂在制备抗肿瘤药物中的联合应用
RU2379032C9 (ru) Комбинации, включающие эпотилоны, и их фармацевтическое применение
WO2023006954A1 (en) Asenapine for use in cancer
HK1161114B (en) Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms
JP2026513685A (ja) 局所進行切除不能または転移性大腸癌の治療に用いられる薬剤およびその使用
JP2015163591A (ja) 抗癌剤の併用による癌治療方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1173090

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120912